Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons.

Babiloni C, Blinowska K, Bonanni L, Cichocki A, De Haan W, Del Percio C, Dubois B, Escudero J, Fernández A, Frisoni G, Guntekin B, Hajos M, Hampel H, Ifeachor E, Kilborn K, Kumar S, Johnsen K, Johannsson M, Jeong J, LeBeau F, Lizio R, Lopes da Silva F, Maestú F, McGeown WJ, McKeith I, Moretti DV, Nobili F, Olichney J, Onofrj M, Palop JJ, Rowan M, Stocchi F, Struzik ZM, Tanila H, Teipel S, Taylor JP, Weiergräber M, Yener G, Young-Pearse T, Drinkenburg WH, Randall F.

Neurobiol Aging. 2019 Sep 19;85:58-73. doi: 10.1016/j.neurobiolaging.2019.09.008. [Epub ahead of print] Review.

PMID:
31739167
2.

Age-dependent emergence of neurophysiological and behavioral abnormalities in progranulin-deficient mice.

Nagy D, Martens LH, Leventhal L, Chen A, Kelley C, Stoiljkovic M, Hajós M.

Alzheimers Res Ther. 2019 Oct 22;11(1):88. doi: 10.1186/s13195-019-0540-x.

3.

Evoked potentials as a translatable biomarker to track functional remyelination.

Farley BJ, Morozova E, Dion J, Wang B, Harvey BD, Gianni D, Wipke B, Cadavid D, Wittmann M, Hajos M.

Mol Cell Neurosci. 2019 Sep;99:103393. doi: 10.1016/j.mcn.2019.103393. Epub 2019 Jul 26.

4.

Neurophysiological signals as predictive translational biomarkers for Alzheimer's disease treatment: effects of donepezil on neuronal network oscillations in TgF344-AD rats.

Stoiljkovic M, Kelley C, Horvath TL, Hajós M.

Alzheimers Res Ther. 2018 Oct 10;10(1):105. doi: 10.1186/s13195-018-0433-4.

5.

Altered Cortical and Hippocampal Excitability in TgF344-AD Rats Modeling Alzheimer's Disease Pathology.

Stoiljkovic M, Kelley C, Stutz B, Horvath TL, Hajós M.

Cereb Cortex. 2019 Jun 1;29(6):2716-2727. doi: 10.1093/cercor/bhy140.

PMID:
29920597
6.

Correction to Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.

Helal CJ, Arnold EP, Boyden TL, Chang C, Chappie TA, Fennell KF, Forman MD, Hajos M, Harms JF, Hoffman WE, Humphrey JM, Kang Z, Kleiman RJ, Kormos BL, LaChapelle EA, Lee CW, Lu J, Maklad N, McDowell L, Mente S, O'Connor RE, Pandit J, Piotrowski M, Schmidt AW, Schmidt CJ, Ueno H, Verhoest PR, Yang EX.

J Med Chem. 2018 Apr 26;61(8):3753. doi: 10.1021/acs.jmedchem.8b00475. Epub 2018 Apr 6. No abstract available.

PMID:
29624389
7.

Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans.

Skosnik PD, Hajós M, Cortes-Briones JA, Edwards CR, Pittman BP, Hoffmann WE, Sewell AR, D'Souza DC, Ranganathan M.

Neuropharmacology. 2018 Jun;135:412-423. doi: 10.1016/j.neuropharm.2018.03.036. Epub 2018 Mar 28.

8.

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.

Helal CJ, Arnold E, Boyden T, Chang C, Chappie TA, Fisher E, Hajos M, Harms JF, Hoffman WE, Humphrey JM, Pandit J, Kang Z, Kleiman RJ, Kormos BL, Lee CW, Lu J, Maklad N, McDowell L, McGinnis D, O'Connor RE, O'Donnell CJ, Ogden A, Piotrowski M, Schmidt CJ, Seymour PA, Ueno H, Vansell N, Verhoest PR, Yang EX.

J Med Chem. 2018 Feb 8;61(3):1001-1018. doi: 10.1021/acs.jmedchem.7b01466. Epub 2018 Jan 16.

PMID:
29293004
9.

Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.

Helal CJ, Arnold EP, Boyden TL, Chang C, Chappie TA, Fennell KF, Forman MD, Hajos M, Harms JF, Hoffman WE, Humphrey JM, Kang Z, Kleiman RJ, Kormos BL, Lee CW, Lu J, Maklad N, McDowell L, Mente S, O'Connor RE, Pandit J, Piotrowski M, Schmidt AW, Schmidt CJ, Ueno H, Verhoest PR, Yang EX.

J Med Chem. 2017 Jul 13;60(13):5673-5698. doi: 10.1021/acs.jmedchem.7b00397. Epub 2017 Jun 16. Erratum in: J Med Chem. 2018 Apr 26;61(8):3753.

PMID:
28574706
10.

Activation of α7 nicotinic acetylcholine receptors facilitates long-term potentiation at the hippocampal-prefrontal cortex synapses in vivo.

Stoiljkovic M, Kelley C, Nagy D, Hurst R, Hajós M.

Eur Neuropsychopharmacol. 2016 Dec;26(12):2018-2023. doi: 10.1016/j.euroneuro.2016.11.003. Epub 2016 Nov 17.

PMID:
27866776
11.

Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS.

Artigas F, Schenker E, Celada P, Spedding M, Lladó-Pelfort L, Jurado N, Núñez M, Santana N, Troyano-Rodriguez E, Riga MS, van den Munkhof H, Castañé A, Shaban H, Jay TM, Tripathi A, Godsil BP, Sebban C, Mariani J, Faure P, Takkilah S, Hughes ZA, Siok CJ, Hajos M, Wicke K, Gass N, Weber-Fahr W, Sartorius A, Becker R, Didriksen M, Bastlund JF, Tricklebank M, Risterucci C, Meyer-Lindenberg A, Schwarz AJ.

Nat Rev Drug Discov. 2017 Jan;16(1):1-2. doi: 10.1038/nrd.2016.205. Epub 2016 Nov 4.

PMID:
27811930
12.

Hippocampal network dynamics in response to α7 nACh receptors activation in amyloid-β overproducing transgenic mice.

Stoiljkovic M, Kelley C, Hajós GP, Nagy D, Koenig G, Leventhal L, Hajós M.

Neurobiol Aging. 2016 Sep;45:161-168. doi: 10.1016/j.neurobiolaging.2016.05.021. Epub 2016 Jun 6.

PMID:
27459936
13.

Selective activation of α7 nicotinic acetylcholine receptors augments hippocampal oscillations.

Stoiljkovic M, Kelley C, Nagy D, Leventhal L, Hajós M.

Neuropharmacology. 2016 Nov;110(Pt A):102-108. doi: 10.1016/j.neuropharm.2016.07.010. Epub 2016 Jul 12.

PMID:
27422408
14.

Role of mitochondrial uncoupling protein-2 (UCP2) in higher brain functions, neuronal plasticity and network oscillation.

Hermes G, Nagy D, Waterson M, Zsarnovszky A, Varela L, Hajos M, Horvath TL.

Mol Metab. 2016 Apr 9;5(6):415-421. doi: 10.1016/j.molmet.2016.04.002. eCollection 2016 Jun.

15.

Modulation of anxiety and fear via distinct intrahippocampal circuits.

Engin E, Smith KS, Gao Y, Nagy D, Foster RA, Tsvetkov E, Keist R, Crestani F, Fritschy JM, Bolshakov VY, Hajos M, Heldt SA, Rudolph U.

Elife. 2016 Mar 14;5:e14120. doi: 10.7554/eLife.14120.

16.

It's All in the Rhythm: The Role of Cannabinoids in Neural Oscillations and Psychosis.

Skosnik PD, Cortes-Briones JA, Hajós M.

Biol Psychiatry. 2016 Apr 1;79(7):568-77. doi: 10.1016/j.biopsych.2015.12.011. Epub 2015 Dec 19. Review.

PMID:
26850792
17.

Neuronal network activity in the hippocampus of tau transgenic (Tg4510) mice.

Scott L, Kiss T, Kawabe TT, Hajós M.

Neurobiol Aging. 2016 Jan;37:66-73. doi: 10.1016/j.neurobiolaging.2015.10.002. Epub 2015 Oct 14.

PMID:
26610388
18.

Inhibition of kynurenine aminotransferase II reduces activity of midbrain dopamine neurons.

Linderholm KR, Alm MT, Larsson MK, Olsson SK, Goiny M, Hajos M, Erhardt S, Engberg G.

Neuropharmacology. 2016 Mar;102:42-7. doi: 10.1016/j.neuropharm.2015.10.028. Epub 2015 Oct 24.

19.

Differential Effects of an NR2B NAM and Ketamine on Synaptic Potentiation and Gamma Synchrony: Relevance to Rapid-Onset Antidepressant Efficacy.

Nagy D, Stoiljkovic M, Menniti FS, Hajós M.

Neuropsychopharmacology. 2016 May;41(6):1486-94. doi: 10.1038/npp.2015.298. Epub 2015 Sep 25.

20.

Modulation of hippocampal neuronal network oscillations by α7 nACh receptors.

Stoiljkovic M, Kelley C, Nagy D, Hajós M.

Biochem Pharmacol. 2015 Oct 15;97(4):445-453. doi: 10.1016/j.bcp.2015.06.031. Epub 2015 Jul 21. Review.

PMID:
26206189
21.

Concentration-response relationship of the α7 nicotinic acetylcholine receptor agonist FRM-17874 across multiple in vitro and in vivo assays.

Stoiljkovic M, Leventhal L, Chen A, Chen T, Driscoll R, Flood D, Hodgdon H, Hurst R, Nagy D, Piser T, Tang C, Townsend M, Tu Z, Bertrand D, Koenig G, Hajós M.

Biochem Pharmacol. 2015 Oct 15;97(4):576-589. doi: 10.1016/j.bcp.2015.07.006. Epub 2015 Jul 20.

PMID:
26206187
22.

The discovery and characterization of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator N-{(3S,4S)-4-[4-(5-cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242).

Shaffer CL, Patel NC, Schwarz J, Scialis RJ, Wei Y, Hou XJ, Xie L, Karki K, Bryce DK, Osgood SM, Hoffmann WE, Lazzaro JT, Chang C, McGinnis DF, Lotarski SM, Liu J, Obach RS, Weber ML, Chen L, Zasadny KR, Seymour PA, Schmidt CJ, Hajós M, Hurst RS, Pandit J, O'Donnell CJ.

J Med Chem. 2015 May 28;58(10):4291-308. doi: 10.1021/acs.jmedchem.5b00300. Epub 2015 May 14.

PMID:
25905800
23.

Application of neurophysiological biomarkers for Huntington's disease: evaluating a phosphodiesterase 9A inhibitor.

Nagy D, Tingley FD 3rd, Stoiljkovic M, Hajós M.

Exp Neurol. 2015 Jan;263:122-31. doi: 10.1016/j.expneurol.2014.10.001. Epub 2014 Oct 12.

PMID:
25315303
24.

Reduction of brain kynurenic acid improves cognitive function.

Kozak R, Campbell BM, Strick CA, Horner W, Hoffmann WE, Kiss T, Chapin DS, McGinnis D, Abbott AL, Roberts BM, Fonseca K, Guanowsky V, Young DA, Seymour PA, Dounay A, Hajos M, Williams GV, Castner SA.

J Neurosci. 2014 Aug 6;34(32):10592-602. doi: 10.1523/JNEUROSCI.1107-14.2014.

25.

Portraying inhibition of metabotropic glutamate receptor 5 in fragile X mice.

Hajós M.

Biol Psychiatry. 2014 Feb 1;75(3):177-8. doi: 10.1016/j.biopsych.2013.11.014. No abstract available.

PMID:
24370351
26.

Discovery and characterization of a novel dihydroisoxazole class of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiators.

Patel NC, Schwarz J, Hou XJ, Hoover DJ, Xie L, Fliri AJ, Gallaschun RJ, Lazzaro JT, Bryce DK, Hoffmann WE, Hanks AN, McGinnis D, Marr ES, Gazard JL, Hajós M, Scialis RJ, Hurst RS, Shaffer CL, Pandit J, O'Donnell CJ.

J Med Chem. 2013 Nov 27;56(22):9180-91. doi: 10.1021/jm401274b. Epub 2013 Nov 11.

PMID:
24215237
27.

Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574.

Shaffer CL, Hurst RS, Scialis RJ, Osgood SM, Bryce DK, Hoffmann WE, Lazzaro JT, Hanks AN, Lotarski S, Weber ML, Liu J, Menniti FS, Schmidt CJ, Hajós M.

J Pharmacol Exp Ther. 2013 Oct;347(1):212-24. doi: 10.1124/jpet.113.204735. Epub 2013 Jul 30.

PMID:
23899905
28.

Neurophysiological signals as potential translatable biomarkers for modulation of metabotropic glutamate 5 receptors.

Harvey BD, Siok CJ, Kiss T, Volfson D, Grimwood S, Shaffer CL, Hajós M.

Neuropharmacology. 2013 Dec;75:19-30. doi: 10.1016/j.neuropharm.2013.06.020. Epub 2013 Jul 4.

PMID:
23831682
29.

Effects of the γ-secretase inhibitor semagacestat on hippocampal neuronal network oscillation.

Hajós M, Morozova E, Siok C, Atchison K, Nolan CE, Riddell D, Kiss T, Hajós-Korcsok E.

Front Pharmacol. 2013 Jun 14;4:72. doi: 10.3389/fphar.2013.00072. eCollection 2013.

30.

Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits.

Kocsis B, Brown RE, McCarley RW, Hajos M.

CNS Neurosci Ther. 2013 Jun;19(6):437-47. doi: 10.1111/cns.12081. Epub 2013 Apr 24. Review.

31.

Rhythmic theta and delta activity of cortical and hippocampal neuronal networks in genetically or pharmacologically induced N-methyl-D-aspartate receptor hypofunction under urethane anesthesia.

Kiss T, Feng J, Hoffmann WE, Shaffer CL, Hajós M.

Neuroscience. 2013 May 1;237:255-67. doi: 10.1016/j.neuroscience.2013.01.058. Epub 2013 Feb 8.

PMID:
23396086
32.

Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation.

Ly S, Pishdari B, Lok LL, Hajos M, Kocsis B.

ACS Chem Neurosci. 2013 Jan 16;4(1):191-9. doi: 10.1021/cn300184t. Epub 2012 Dec 10.

33.

Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.

Claffey MM, Helal CJ, Verhoest PR, Kang Z, Fors KS, Jung S, Zhong J, Bundesmann MW, Hou X, Lui S, Kleiman RJ, Vanase-Frawley M, Schmidt AW, Menniti F, Schmidt CJ, Hoffman WE, Hajos M, McDowell L, O'Connor RE, Macdougall-Murphy M, Fonseca KR, Becker SL, Nelson FR, Liras S.

J Med Chem. 2012 Nov 8;55(21):9055-68. doi: 10.1021/jm3009635. Epub 2012 Oct 12.

PMID:
23025719
34.

The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal θ oscillations.

Johnson DE, Drummond E, Grimwood S, Sawant-Basak A, Miller E, Tseng E, McDowell LL, Vanase-Frawley MA, Fisher KE, Rubitski DM, Stutzman-Engwall KJ, Nelson RT, Horner WE, Gorczyca RR, Hajos M, Siok CJ.

J Pharmacol Exp Ther. 2012 Jun;341(3):681-91. doi: 10.1124/jpet.112.192351. Epub 2012 Mar 9.

PMID:
22408061
35.

Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.

Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF, Grimwood S, Guanowsky V, Hajós M, Harms JF, Helal CJ, Hoffmann WE, Kocan GP, Majchrzak MJ, McGinnis D, McLean S, Menniti FS, Nelson F, Roof R, Schmidt AW, Seymour PA, Stephenson DT, Tingley FD, Vanase-Frawley M, Verhoest PR, Schmidt CJ.

J Pharmacol Exp Ther. 2012 May;341(2):396-409. doi: 10.1124/jpet.111.191353. Epub 2012 Feb 10.

PMID:
22328573
36.

Age-dependent disruption in hippocampal θ oscillation in amyloid-β overproducing transgenic mice.

Scott L, Feng J, Kiss T, Needle E, Atchison K, Kawabe TT, Milici AJ, Hajós-Korcsok E, Riddell D, Hajós M.

Neurobiol Aging. 2012 Jul;33(7):1481.e13-23. doi: 10.1016/j.neurobiolaging.2011.12.010. Epub 2012 Jan 9.

PMID:
22227005
37.

Translating glutamate: from pathophysiology to treatment.

Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K, Bear MF, Umbricht D, Hajos M, Potter WZ, Lee CM.

Sci Transl Med. 2011 Sep 28;3(102):102mr2. doi: 10.1126/scitranslmed.3002804. Review.

38.

Comparative analysis of the neurophysiological profile of group II metabotropic glutamate receptor activators and diazepam: effects on hippocampal and cortical EEG patterns in rats.

Siok CJ, Cogan SM, Shifflett LB, Doran AC, Kocsis B, Hajós M.

Neuropharmacology. 2012 Jan;62(1):226-36. doi: 10.1016/j.neuropharm.2011.07.011. Epub 2011 Jul 26.

PMID:
21791219
39.

Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain.

Strick CA, Li C, Scott L, Harvey B, Hajós M, Steyn SJ, Piotrowski MA, James LC, Downs JT, Rago B, Becker SL, El-Kattan A, Xu Y, Ganong AH, Tingley FD 3rd, Ramirez AD, Seymour PA, Guanowsky V, Majchrzak MJ, Fox CB, Schmidt CJ, Duplantier AJ.

Neuropharmacology. 2011 Oct-Nov;61(5-6):1001-15. doi: 10.1016/j.neuropharm.2011.06.029. Epub 2011 Jul 7.

PMID:
21763704
40.

Role of Thalamic Projection in NMDA Receptor-Induced Disruption of Cortical Slow Oscillation and Short-Term Plasticity.

Kiss T, Hoffmann WE, Scott L, Kawabe TT, Milici AJ, Nilsen EA, Hajós M.

Front Psychiatry. 2011 Apr 4;2:14. doi: 10.3389/fpsyt.2011.00014. eCollection 2011.

41.

EEG coherence and symptom profiles of children with Attention-Deficit/Hyperactivity Disorder.

Barry RJ, Clarke AR, Hajos M, Dupuy FE, McCarthy R, Selikowitz M.

Clin Neurophysiol. 2011 Jul;122(7):1327-32. doi: 10.1016/j.clinph.2011.01.007. Epub 2011 Feb 9.

PMID:
21310652
42.

Control of hippocampal theta rhythm by serotonin: role of 5-HT2c receptors.

Sörman E, Wang D, Hajos M, Kocsis B.

Neuropharmacology. 2011 Sep;61(3):489-94. doi: 10.1016/j.neuropharm.2011.01.029. Epub 2011 Jan 31.

43.

Resting-state EEG gamma activity in children with attention-deficit/hyperactivity disorder.

Barry RJ, Clarke AR, Hajos M, McCarthy R, Selikowitz M, Dupuy FE.

Clin Neurophysiol. 2010 Nov;121(11):1871-7. doi: 10.1016/j.clinph.2010.04.022. Epub 2010 May 18.

PMID:
20483659
44.

Delta oscillation and short-term plasticity in the rat medial prefrontal cortex: modelling NMDA hypofunction of schizophrenia.

Kiss T, Hoffmann WE, Hajós M.

Int J Neuropsychopharmacol. 2011 Feb;14(1):29-42. doi: 10.1017/S1461145710000271. Epub 2010 Mar 25.

PMID:
20334724
45.

Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition models.

O'Donnell CJ, Rogers BN, Bronk BS, Bryce DK, Coe JW, Cook KK, Duplantier AJ, Evrard E, Hajós M, Hoffmann WE, Hurst RS, Maklad N, Mather RJ, McLean S, Nedza FM, O'Neill BT, Peng L, Qian W, Rottas MM, Sands SB, Schmidt AW, Shrikhande AV, Spracklin DK, Wong DF, Zhang A, Zhang L.

J Med Chem. 2010 Feb 11;53(3):1222-37. doi: 10.1021/jm9015075.

PMID:
20043678
46.

Challenges in progressing schizophrenia therapy.

Hajós M.

Front Psychiatry. 2010 Mar 17;1:9. doi: 10.3389/fpsyt.2010.00009. eCollection 2010. No abstract available.

47.

Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia.

Hajós M, Rogers BN.

Curr Pharm Des. 2010;16(5):538-54. Review.

PMID:
19909231
48.

Acute atomoxetine effects on the EEG of children with attention-deficit/hyperactivity disorder.

Barry RJ, Clarke AR, Hajos M, McCarthy R, Selikowitz M, Bruggemann JM.

Neuropharmacology. 2009 Dec;57(7-8):702-7. doi: 10.1016/j.neuropharm.2009.08.003. Epub 2009 Aug 19.

PMID:
19698723
49.

Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition.

Rollema H, Hajós M, Seymour PA, Kozak R, Majchrzak MJ, Guanowsky V, Horner WE, Chapin DS, Hoffmann WE, Johnson DE, McLean S, Freeman J, Williams KE.

Biochem Pharmacol. 2009 Oct 1;78(7):813-24. doi: 10.1016/j.bcp.2009.05.033. Epub 2009 Jun 6.

PMID:
19501054
50.

Anxiolytic profile of pregabalin on elicited hippocampal theta oscillation.

Siok CJ, Taylor CP, Hajós M.

Neuropharmacology. 2009 Feb;56(2):379-85. doi: 10.1016/j.neuropharm.2008.09.013. Epub 2008 Oct 7.

PMID:
18930748

Supplemental Content

Support Center